Figure 4From: KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cellsDifferential effect of ARRY-520 and Paclitaxel on NF-κB activation in Type I EOC cells. Cells were transfected with a luciferase reporter plasmid activated by NF-κB and treated with either 3 μM ARRY-520 or 2 μM Paclitaxel. NF-κB activity was measured as luminescence. Data shown are for R182 cells. Similar results were obtained with other Type I EOC cells tested.Back to article page